Title:
Anti-GD2 antibody
Document Type and Number:
Japanese Patent JP6029581
Kind Code:
B2
Abstract:
In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.
Inventors:
Chan, Nikong
Ahmed, Mahydine
Ahmed, Mahydine
Application Number:
JP2013515579A
Publication Date:
November 24, 2016
Filing Date:
June 20, 2011
Export Citation:
Assignee:
Memorial Sloan-Kettering Cancer Center
International Classes:
C12N15/09; A61K38/00; A61K39/395; A61K45/00; A61P35/00; A61P35/02; C07K14/705; C07K16/28; C07K16/30; C07K16/44; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12P21/02; C12P21/08
Domestic Patent References:
| JP2005511706A | ||||
| JP2002532079A | ||||
| JP2008505174A | ||||
| JP2009506790A |
Foreign References:
| WO1992018629A1 |
Other References:
JOURNAL OF CLINICAL ONCOLOGY, 2001, vol 19, no.22 p.4189-4194
MOLECULAR THERAPY, 2004, vol.10, no.1, p.5-18
MOLECULAR THERAPY, 2004, vol.10, no.1, p.5-18
Attorney, Agent or Firm:
Taro Yaguchi
Previous Patent: The optical article which uses a photochromic constituent and the constituent
Next Patent: THAWER
Next Patent: THAWER